Download PDF
Semin Thromb Hemost 2003; 29(2): 165-170
DOI: 10.1055/s-2003-38831
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Thrombophilia and Fetal Loss

Benjamin Brenner
  • Director, Thrombosis and Hemostasis Unit, Department of Hematology, Rambam Medical Center, Haifa, Israel
Further Information

Publication History

Publication Date:
23 April 2003 (online)

    Permissions and Reprints

ABSTRACT

A large body of evidence obtained during the last 6 years suggests a significant role for inherited thrombophilia in the development of gestational vascular complications. Case-control studies demonstrated that thrombophilia is more prevalent in cohorts of women with pregnancy loss. Other complications such as preeclampsia, placental abruption, and intrauterine growth retardation may also be associated with thrombophilia. Placental pathologic findings in women with thrombophilia are hallmarked by thrombosis and fibrin deposition. Preliminary case-control studies suggest that low-molecular-weight heparins are effective in preventing pregnancy loss in women with thrombophilia and previous fetal wastage.

KEYWORDS

Thrombophilia - pregnancy - pregnancy loss - preeclampsia - low-molecular-weight heparin

REFERENCES

  • 1 Salafia C M, Minior V K, Pezzullo J C. et al . Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features.  Am J Obstet Gynecol . 1995;  173 1049-1057
    CrossrefPubMedGoogle Scholar
  • 2 Cook C L, Pridham D D. Recurrent pregnancy loss.  Curr Opin Obstet Gynecol . 1995;  7 357-366
    PubMedGoogle Scholar
  • 3 Clifford K, Rai R, Watson H, Regan L. An informative protocol for the investigation of recurrent miscarriage: preliminary experience of 500 consecutive cases.  Human Reprod . 1994;  9 1328-1332
    PubMedGoogle Scholar
  • 4 Hatasaka H H. Recurrent miscarriage: epidemiologic factors, definitions, and incidence.  Clin Obstet Gynecol . 1994;  37 625-634
    CrossrefPubMedGoogle Scholar
  • 5 Raziel A, Arieli S, Bukovsky I, Caspi E, Golan A. Investigation of the uterine cavity in recurrent aborters.  Fertil Steril . 1994;  62 1080-1082
    PubMedGoogle Scholar
  • 6 Sanson B J, Friederich P W, Simioni P. et al . The risk of abortion and stillbirth in antithrombin, protein C, and protein S-deficient women.  Thromb Haemost . 1996;  75 387-388
    PubMedGoogle Scholar
  • 7 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.  Thromb Haemost . 1995;  73 151-161
    PubMedGoogle Scholar
  • 8 Rikder P M, Miletich J P, Buring J E. et al . Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.  Ann Intern Med . 1998;  128 1000-1003
    PubMedGoogle Scholar
  • 9 Grandone E, Margaglione M, Colaizzo D. et al . Factor V Leiden is associated with repeated and recurrent unexplained fetal losses.  Thromb Haemost . 1997;  77 822-824
    PubMedGoogle Scholar
  • 10 Brenner B, Sarig G, Weiner Z. et al . Thrombophilic polymorphisms in women with fetal loss.  Thromb Haemost . 1999;  82 6-9
    PubMedGoogle Scholar
  • 11 Sarig G, Hoffman R, Younis J. et al . Thrombophilia is common in women with pregnancy loss and is associated with late pregnancy wastage.  Fertil Steril . 2002;  77 342-347
    CrossrefPubMedGoogle Scholar
  • 12 Dizon-Townson D S, Kinney S, Branch D W, Ward K. The factor V Leiden mutation is not a common cause of recurrent miscarriage.  J Reprod Immunol . 1997;  34 217-223
    PubMedGoogle Scholar
  • 13 Roque H, Paidas M, Rebarber A. et al . Maternal thrombophilia is associated with second and third trimester fetal death (Abst).  Am J Obstet Gynecol . 2001;  184 S27
    PubMedGoogle Scholar
  • 14 Younis J S, Brenner B, Ohel G. et al . Activated protein C resistance and factor V Leiden mutation can with first- as well as second-trimester recurrent pregnancy loss.  Am J Reprod Immunol . 2000;  43 31-35
    CrossrefPubMedGoogle Scholar
  • 15 Wramsby M L, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation.  Fertil Steril . 2000;  74 987-991
    CrossrefPubMedGoogle Scholar
  • 16 Meinardi J R, Middeldorp S, de Kam J P. et al . Increased risk for fetal loss in carriers of the factor V Leiden mutation.  Ann Intern Med . 1999;  130 736-739
    PubMedGoogle Scholar
  • 17 Tormene D, Simioni P, Prandoni P. et al . The risk of fetal loss in family member of probands with factor V Leiden mutation.  Thromb Haemost . 1999;  82 1237-1239
    PubMedGoogle Scholar
  • 18 Eichinger S, Weltermann A, Philipp K. et al . Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.  Thromb Haemost . 1999;  82 1232-1236
    PubMedGoogle Scholar
  • 19 Clark P, Brennand J, Conkie J A. et al . Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy.  Thromb Haemost . 1998;  79 1166-1170
    PubMedGoogle Scholar
  • 20 Kjelberg U, Andersson N E, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium.  Thromb Haemost . 1999;  81 527-531
    PubMedGoogle Scholar
  • 21 Tal J, Schliamser L M, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure.  Hum Reprod . 1999;  14 1624-1627
    CrossrefPubMedGoogle Scholar
  • 22 Brenner B, Mandel H, Lanir N. et al . Activated protein C resistance can be associated with recurrent fetal loss.  Br J Haematol . 1997;  97 551-554
    CrossrefPubMedGoogle Scholar
  • 23 Mercier E, Quere I, Mares P, Gris J C. Primary recurrent miscarriages: anti-β2-glycoprotein I IgG antibodies induce an acquired activated protein C resistance that can be detected by the modified activated protein C resistance test.  Blood . 1998;  92 2993-2994
    PubMedGoogle Scholar
  • 24 Souza S S, Ferriani R A, Pontes A G, Zago M A, Franco R F. Factor V Leiden and factor II G20210A mutations in patients with recurrent abortion.  Hum Reprod . 1999;  14 2448-2450
    CrossrefPubMedGoogle Scholar
  • 25 Martinelli I, Taioli E, Cetin I. et al . Mutations in coagulation factors in women with unexplained late fetal loss.  N Engl J Med . 2000;  343 1015-1018
    CrossrefPubMedGoogle Scholar
  • 26 de Vries I P J, Dekker G A, Huijgens P C. et al . Hyperhomocysteinaemia and protein S deficiency in complicated pregnancies.  Br J Obstet Gynaecol . 1997;  104 1248-1254
    CrossrefPubMedGoogle Scholar
  • 27 Goddijn-Wessel T A, Wouters M G, van der Molen F E. et al . Hyper-homocysteinemia: a risk factor for placental abruption or infarction.  Eur J Obstet Gynecol Rep Biol . 1996;  66 23-29
    CrossrefPubMedGoogle Scholar
  • 28 Coumans A B, Huijgens P C, Jakobs C. et al . Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.  Hum Reprod . 1999;  14 211-214
    CrossrefPubMedGoogle Scholar
  • 29 Nelen W D M L, Blom H J, Steegers E AP, den Heijer M, Eskes T A B K. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis.  Fertil Steril . 2000;  74 1196-1199
    CrossrefPubMedGoogle Scholar
  • 30 Züller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.  Blood . 1995;  85 3518-3523
    PubMedGoogle Scholar
  • 31 Brenner B, Zivelin A, Lanir N. et al . Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C deficient newborn with massive thrombosis.  Blood . 1996;  88 877-880
    PubMedGoogle Scholar
  • 32 Mandel H, Brenner B, Berant M. et al . Coexistence of hereditary homocysteinuria and factor V Leiden-effect on thrombosis.  N Engl J Med . 1996;  334 763-768
    CrossrefPubMedGoogle Scholar
  • 33 Brenner B, Vulfsons S L, Lanir N, Nahir M. Coexistence of familial antiphospholipid syndrome and factor V Leiden-impact on thrombotic diathesis.  Br J Haematol . 1996;  94 166-167
    CrossrefPubMedGoogle Scholar
  • 34 Preston F E, Rosendaal F R, Walker I D. et al . Increased fetal loss in women with heritable thrombophilia.  Lancet . 1996;  348 913-916
    CrossrefPubMedGoogle Scholar
  • 35 Gris J C, Quere I, Monpeyroux F. et al . Case-control study of the frequency of thrombophilic disorders in couples with late foetal-loss and no thrombotic antecedent-the Nimes Obstetricians and Haematologists Study 5 (NOHA5).  Thromb Haemost . 1999;  81 891-899
    PubMedGoogle Scholar
  • 36 Mousa H A, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?.  Hum Reprod . 2000;  15 1830-1833
    CrossrefPubMedGoogle Scholar
  • 37 Dizon-Townson D S, Meline L, Nelson L M, Varner M, War K. Fetal carriers of the factor V Leiden mutation are prone to miscarriage and placental infarction.  Am J Obstet Gynecol . 1997;  177 402-405
    CrossrefPubMedGoogle Scholar
  • 38 Kupferminc M J, Eldor A, Steinman N. et al . Increased frequency of genetic thrombophilias in women with complications of pregnancy.  N Engl J Med . 1999;  340 9-13
    CrossrefPubMedGoogle Scholar
  • 39 Grandone E, Margaglione M, Colaizzo D. et al . Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations.  Am J Obstet Gynecol . 1998;  179 1324-1328
    CrossrefPubMedGoogle Scholar
  • 40 Many A, Schreiber I, Rosner S. et al . Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia.  Obstet Gynecol . 2001;  98 1041-1044
    CrossrefPubMedGoogle Scholar
  • 41 Sanson B J, Lensing A WA, Prins M H, Ginsberg J S, Büller H R. The use of low molecular weight heparin in pregnancy (Abst).  Blood . 1998;  92(Suppl 1) 360A
    PubMedGoogle Scholar
  • 42 Gris J C, Neveu S, Tailland M L. et al . Use of low-molecular weight heparin (Enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity.  Thromb Haemost . 1995;  73 362-367
    PubMedGoogle Scholar
  • 43 Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.  Thromb Haemost . 2000;  83 693-697
    PubMedGoogle Scholar
  • 44 Nakabayashi M, Yamamoto S, Suzuki K. Analysis of thrombomodulin gene polymorphism in women with severe early-onset preeclampsia.  Semin Thromb Hemost . 1999;  25 473-479
    PubMedGoogle Scholar
  • 45 Franchi F, Biguzzi E, Cetin I. et al . Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss.  Br J Haematol . 2001;  114 641-646
    CrossrefPubMedGoogle Scholar
  • 46 Yamada H, Kato E H, Ebina Y. et al . Factor XII deficiency in women with recurrent miscarriage.  Gynecol Obstet Invest . 2000;  49 80-83
    CrossrefPubMedGoogle Scholar
  • 47 Glueck C J, Kupferminc M J, Fontaine R N. et al . Genetic hypofibrinolysis in complicated pregnancies.  Obstet Gynecol . 2001;  97 44-48
    CrossrefPubMedGoogle Scholar
  • 48 Laude I, Rongieres-Bertrand C, Boyer-Neumann C. et al . Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight.  Thromb Haemost . 2001;  85 18-21
    PubMedGoogle Scholar
  • 49 Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with idiopathic pregnancy loss.  Thromb Haemost . 2002;  88 32-36
    PubMedGoogle Scholar